GlassScriptPhysician profile
Shawn Mcclure
NPI 1265084859
$2,191.82
in general payments reported to CMS, 2019-2025
15 companies · $67.47 in 2025
The $67.47 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $653 · 2023: $623 · 2024: $603 · 2025: $67.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $505.19 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $454.81 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $165.56 | 2022-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $150.93 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $129.24 | 2021-2024 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $121.49 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $114.29 | 2024 | Quviviq |
| Alkermes, INC. | $107.84 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $107.72 | 2022-2023 | Austedo |
| Tris Pharma INC | $99.80 | 2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Viiv Healthcare Company | $93.64 | 2024 | Cabenuva |
| E.R. Squibb & Sons, L.L.C. | $48.79 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $38.47 | 2021 | |
| Lundbeck LLC | $34.18 | 2021-2023 | Rexulti |
| Indivior INC. | $19.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.